Restructuring, Impairment and Related Charges (Tables)

9 Months Ended

Dec. 31, 2020

Restructuring and Related Activities [Abstract]

Restructuring, Impairment and Related Costs

Restructuring, impairment, and related charges during the three and nine months ended December 31, 2020 consisted of the following:

	Three Months Ended December 31, 2020
(In millions)	U.S. Pharmaceutical		International (1)		Medical-Surgical Solutions		Prescription Technology Solutions		Corporate (2)		Total
Severance and employee-related costs, net	$	3	$	2	$	(3)	$	—	$	7	$	9
Exit and other-related costs (3)	3		5		1		—		6		15
Asset impairments and accelerated depreciation	—		9		—		—		7		16
Total	$	6	$	16	$	(2)	$	—	$	20	$	40

(1)Primarily represents costs associated with the operating model and cost optimization efforts described above.

(2)Represents costs associated with the operating model cost optimization efforts and with the relocation of the Company’s corporate headquarters described above.

(3)Exit and other-related costs primarily consist of project consulting fees.

	Nine Months Ended December 31, 2020
(In millions)	U.S. Pharmaceutical		International (1)		Medical-Surgical Solutions		Prescription Technology Solutions		Corporate (2)		Total
Severance and employee-related costs, net	$	10	$	22	$	—	$	—	$	31	$	63
Exit and other-related costs (3)	8		12		3		—		20		43
Asset impairments and accelerated depreciation	—		40		1		—		9		50
Total	$	18	$	74	$	4	$	—	$	60	$	156

(1)Primarily represents costs associated with the operating model and cost optimization efforts described above.

(2)Represents costs associated with the operating model cost optimization efforts and with the relocation of the Company’s corporate headquarters described above.

(3)Exit and other-related costs primarily consist of project consulting fees.

Fiscal 2020

Restructuring, impairment, and related charges during the three and nine months ended December 31, 2019 consisted of the following:

	Three Months Ended December 31, 2019
(In millions)	U.S. Pharmaceutical (1)		International (2)		Medical-Surgical Solutions (3)		Prescription Technology Solutions		Corporate (4)		Total
Severance and employee-related costs, net	$	7	$	1	$	1	$	—	$	7	$	16
Exit and other-related costs (5)	—		3		5		—		13		21
Asset impairments and accelerated depreciation	—		2		—		—		3		5
Total	$	7	$	6	$	6	$	—	$	23	$	42

(1)Represents exit costs associated with a disposition and costs related to the relocation of the Company’s corporate headquarters described above.

(2)Primarily represents costs associated with the operating model and cost optimization efforts described above.

(3)Primarily represents costs associated with a growth initiative which included a reduction in workforce, facility consolidation, and store closures. These initiatives were substantially completed in the year ended March 31, 2020.

(4)Represents costs associated with the operating model cost optimization efforts described above. Additionally, includes costs associated with a growth initiative, substantially completed in the year ended March 31, 2020, which included a reduction in workforce and facility consolidation.

(5)Exit and other-related costs primarily include project consulting fees.

	Nine Months Ended December 31, 2019
(In millions)	U.S. Pharmaceutical (1)		International (2)		Medical-Surgical Solutions (3)		Prescription Technology Solutions		Corporate (4)		Total
Severance and employee-related costs, net	$	9	$	5	$	2	$	—	$	23	$	39
Exit and other-related costs (5)	—		9		9		—		36		54
Asset impairments and accelerated depreciation	—		8		1		—		8		17
Total	$	9	$	22	$	12	$	—	$	67	$	110

(1)Represents exit costs associated with a disposition and costs related to the relocation of the Company’s corporate headquarters described above.

(2)Primarily represents costs associated with the operating model and cost optimization efforts described above.

(3)Primarily represents costs associated with a growth initiative which included a reduction in workforce, facility consolidation, and store closures. These initiatives were substantially completed in the year ended March 31, 2020.

(4)Represents costs associated with the operating model cost optimization efforts and with the relocation of the Company’s corporate headquarters described above. Additionally, includes costs associated with a growth initiative, substantially completed in the year ended March 31, 2020, which included a reduction in workforce and facility consolidation.

(5)Exit and other-related costs primarily include project consulting fees.

Schedule of Restructuring and Asset Impairment Charges

The following table summarizes the activity related to the restructuring liabilities associated with the Company’s restructuring initiatives for the nine months ended December 31, 2020:

(In millions)	U.S. Pharmaceutical		International		Medical-Surgical Solutions		Prescription Technology Solutions		Corporate		Total
Balance, March 31, 2020 (1)	$	29	$	66	$	22	$	1	$	39	$	157
Restructuring, impairment, and related charges	18		74		4		—		60		156
Non-cash charges	—		(40)		(1)		—		(9)		(50)
Cash payments	(24)		(24)		(19)		(1)		(64)		(132)
Other	—		(1)		—		—		2		1
Balance, December 31, 2020 (2)	$	23	$	75	$	6	$	—	$	28	$	132

(1)As of March 31, 2020, the total reserve balance was $157 million, of which $118 million was recorded in Other accrued liabilities and $39 million was recorded in Other non-current liabilities.

(2)As of December 31, 2020, the total reserve balance was $132 million, of which $101 million was recorded in Other accrued liabilities and $31 million was recorded in Other non-current liabilities.